Menu Search
Equities

Luye Pharma Group Ltd

2186:HKG

Luye Pharma Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)2.85
  • Today's Change0.03 / 1.06%
  • Shares traded13.39m
  • 1 Year change-25.97%
  • Beta1.2899
Data delayed at least 15 minutes, as of Nov 08 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Luye Pharma Group Ltd's net income fell -11.94% from 604.81m to 532.61m despite relatively flat revenues. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 40.17% to 43.95%.
Gross margin68.73%
Net profit margin13.18%
Operating margin26.08%
Return on assets3.11%
Return on equity6.33%
Return on investment5.47%
More ▼

Cash flow in CNYView more

In 2023, Luye Pharma Group Ltd increased its cash reserves by 39.39%, or 915.23m. The company earned 1.60bn from its operations for a Cash Flow Margin of 25.97%. In addition the company generated 841.60m cash from financing while 1.42bn was spent on investing.
Cash flow per share0.4485
Price/Cash flow per share6.35
Book value per share3.77
Tangible book value per share1.59
More ▼

Balance sheet in CNYView more

Luye Pharma Group Ltd has a Debt to Total Capital ratio of 41.03%, a higher figure than the previous year's 18.59%.
Current ratio1.28
Quick ratio1.20
Total debt/total equity0.7527
Total debt/total capital0.4103
More ▼

Growth rates in CNY

Year on year, growth in earnings per share excluding extraordinary items dropped -17.78%. Additionally, five year annualized earnings per share growth ranks below the industry average relative to its peers.
EPS growth(5 years)-18.79
EPS (TTM) vs
TTM 1 year ago		58.85
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.